AstraZeneca PLC
AZN
$73.95
$0.861.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.50B | 54.98B | 54.07B | 51.21B | 49.13B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.50B | 54.98B | 54.07B | 51.21B | 49.13B |
| Cost of Revenue | 10.06B | 9.69B | 9.67B | 8.94B | 8.58B |
| Gross Profit | 46.44B | 45.29B | 44.40B | 42.26B | 40.56B |
| SG&A Expenses | 19.46B | 19.54B | 19.59B | 18.22B | 18.41B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -251.00M | -239.00M | -192.00M | -222.00M | -267.00M |
| Total Operating Expenses | 42.52B | 41.74B | 41.51B | 38.69B | 37.98B |
| Operating Income | 13.98B | 13.24B | 12.56B | 12.52B | 11.16B |
| Income Before Tax | 10.02B | 9.29B | 8.69B | 7.92B | 7.75B |
| Income Tax Expenses | 1.72B | 1.51B | 1.65B | 1.42B | 1.30B |
| Earnings from Continuing Operations | 8.30K | 7.78K | 7.04K | 6.50K | 6.45K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -7.00M | -10.00M | -6.00M | -5.00M | -5.00M |
| Net Income | 8.30B | 7.77B | 7.04B | 6.50B | 6.44B |
| EBIT | 13.98B | 13.24B | 12.56B | 12.52B | 11.16B |
| EBITDA | 18.78B | 17.93B | 17.22B | 17.26B | 15.81B |
| EPS Basic | 5.35 | 5.01 | 4.54 | 4.19 | 4.16 |
| Normalized Basic EPS | 5.13 | 4.84 | 4.55 | 4.55 | 3.99 |
| EPS Diluted | 5.31 | 4.97 | 4.50 | 4.15 | 4.12 |
| Normalized Diluted EPS | 5.09 | 4.81 | 4.52 | 4.51 | 3.96 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.25B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 3.13 | 3.10 | 3.10 | 2.97 | 2.97 |
| Payout Ratio | 59.51% | 63.60% | 65.80% | 71.25% | 69.29% |